China pledges more balanced trade and further opening of the economy after record surplus

China reported a record $1.2 trillion goods trade surplus for 2025 and Premier Li Qiang pledged to further open the economy and import more high-quality foreign goods to promote balanced trade. Foreign direct investment is weakening—FDI fell 5.7% y/y to just over ¥92bn (~$13.36bn) in January after a 9.5% decline in 2025—prompting policy steps including incentives across 200 added sectors. PBOC Governor Pan Gongsheng stressed that China's goods surplus is offset by a services deficit and denied any intent to pursue currency depreciation, while officials promised stronger IP protection and transparency to reassure multinational firms.

Analysis

China’s verbal pivot to import more high-quality goods and ease foreign investment frictions is a policy lever aimed at lowering diplomatic costs of a large goods surplus rather than an immediate demand shock. Expect the mechanical demand impact to be concentrated in higher-margin segments (pharma, finished consumer electronics, premium autos) where supply is globally specialized and tariff/NTB barriers were the main constraint; broad-based import growth sufficient to materially cut the $1T+ surplus would take 12–36 months and targeted policy implementation.

Second-order winners are firms whose China revenue is sensitive to regulatory openness and IP clarity — multinational pharma and premium consumer brands gain asymmetric upside from marginal policy improvements because incremental market access directly converts to higher ASPs and faster dossier approvals. Conversely, multinational suppliers of industrial or commodity inputs face muted benefit and elevated competition risk: Beijing’s advanced-manufacturing incentives accelerate local champions, which over 2–5 years will compress OEM supplier margins and create substitute demand that weighs on select Western industrial suppliers.

Key risks are geopolitical tail events and implementation slippage. A formal rollback of tariff truce, renewed export controls, or a sudden RMB re-pricing would reverse flows in weeks; by contrast, an incremental improvement in investment approvals and IP rulings will show up in FDI and multinational capex with a 6–18 month lag. For positions that lean on the China reopening narrative, hedge via modest protection against renewed decoupling or RMB shocks — FX policy comments from the PBOC reduce devaluation tail risk but do not obviate political catalysts that move markets quickly.

Key Decisions for Investors

• Long AAPL via a 9–12 month call spread: buy a 1-year 10% OTM call and sell a 1-year 30% OTM call to express faster China premium-device sales and manufacturing stability. Rationale: asymmetric upside if policy removes frictions on high-end consumer imports; limited premium outlay caps downside to option cost (target 3:1 upside/downside payoff if China discretionary demand normalizes within 12 months).
• Long NVS (novartis) outright or buy 18-month calls to play improved IP protection and faster market access for new drug launches. Rationale: incremental regulatory clarity converts into higher peak sales; target a 12–24 month horizon with a stop-loss at 12% below entry and profit-taking on 30–40% upside.
• Relative-value trade: long HSBC (exposure to China FDI flows and fee pools) vs short UBS (European investment bank with less China franchise) on a 6–12 month horizon. Size equally notional; thesis is widening fee capture and RMB onshore activity benefits HSBC more. Risk: global rate shock or European banking idiosyncrasies could overwhelm China exposure — set 8–12% symmetric stops.
• Tail-hedge: buy a small AVGO 9–12 month put spread (e.g., buy 20% OTM put / sell 35% OTM put) to protect against rapid tech decoupling or export-control shock that would compress Broadcom’s China-facing demand. Cost is modest and preserves upside in other longs while capping losses if geopolitics re-escalate.